Latest news articles

Added 14 days ago Drug news

Phase III ICARIA-MM trial of SAR 650984 shows reduced risk in multiple myeloma.

Pivotal Phase III ICARIA-MM trial results demonstrated that SAR 650984 (isatuximab), from Sanofi, added to pomalidomide and dexamethasone (isatuximab combination...

Added 16 days ago Drug news

Application for Darzalex + Velcade + dexamethasone in multiple myeloma granted priority review by FDA.

The FDA has granted a Priority Review for the supplemental Biologics License Application (sBLA) for the use of Darzalex (daratumumab)...

Added 17 days ago Drug news

Phase III MAIA (MMY3008) study of Darzalex + Revlimid in multiple myeloma published in the NEJM.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase III MAIA...

Search all news articles for Multiple myeloma

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more


Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Multiple myeloma accounts for 1% of all cancers and approximately 10% of all haematological malignancies. These updated ESMO Clinical Practice Guidelines cover the diagnosis and pathology/molecular biology, staging and...

Added 2 years ago

Guidelines for the use of imaging in the management of patients with myeloma

The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging...

Added 1 year ago

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

A growing population of long-term survivors of myeloma isnow accumulating the ‘late effects’ not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease.

Added 1 year ago

Search all guidelines for Multiple myeloma

Journal articles

Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.

Background: Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT...

Added 2 months ago

Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation.

Although peripheral blood stem cells (PBSC) have worldwide become the predominant source of progenitor cells for hematopoietic stem cell transplantation (HSCT), debate about their role compared with bone marrow (BM)...

Added 2 months ago

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

This article summarizes the scientific review of the application leading to regulatory approval in the European Union.

Added 10 months ago

Search all journal articles for Multiple myeloma

Clinical trials

Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Added 11 months ago

Study of lenalidomide and dexamethasone with or without pembrolizumab (MK-3475) in participants with newly diagnosed treatment naive multiple myeloma (MK-3475-185/KEYNOTE-185)

The purpose of this study is to compare the efficacy of adding pembrolizumab to lenalidomide and low dose dexamethasone in participants with treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant (auto-SCT).

Added 1 year ago

Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

The purpose of this study is to compare the efficacy of adding pembrolizumab to pomalidomide and low dose dexamethasone in participants with refractory or relapsed multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment.

Added 1 year ago

Search all clinical trials for Multiple myeloma